# SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)

Study · id `cardio:ct-nct03050229` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03050229](<https://clinicaltrials.gov/study/NCT03050229>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03050229

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 174 participants.

## Technical summary

Registry record NCT03050229. Randomized; quadruple masking; primary purpose treatment. Start 2017-01 (actual); primary completion 2017-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 174 participants (enrolled count; ClinicalTrials.gov record NCT03050229, source copy `cardio:ctgov-nct03050229-2018-03-27`, retrieved 2026-10-26)
- Started: 2017-01 (actual) (ClinicalTrials.gov record NCT03050229, source copy `cardio:ctgov-nct03050229-2018-03-27`, retrieved 2026-10-26)
- Primary completion: 2017-10 (actual) (ClinicalTrials.gov record NCT03050229, source copy `cardio:ctgov-nct03050229-2018-03-27`, retrieved 2026-10-26)
- Completion: 2018-03 (actual) (ClinicalTrials.gov record NCT03050229, source copy `cardio:ctgov-nct03050229-2018-03-27`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT03050229, source copy `cardio:ctgov-nct03050229-2018-03-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03050229-2018-03-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)
- Condition: Nocturnal Hypertension
- Condition: T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug): Empagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Jichi Medical University
- Lead sponsor class: OTHER
- Collaborator: Boehringer Ingelheim
- Collaborator class: INDUSTRY
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as a collaborator: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: dc57d9df85239e6b134c19e697b54ec8c182f0499ae31da435c1eaf8f581e883
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
